---
title: "美国银行证券在 TG 治疗（TGTX）发布财报后持看空态度"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/278261754.md"
description: "美国银行证券在 TG Therapeutics, Inc.（NASDAQ:TGTX）发布财报后重申了其 “卖出” 评级。分析师 Alec Stranahan 设定了 15 美元的目标价，这是华尔街预估中最低的。尽管该公司被列为当前最值得购买的 13 只高利润成长股之一，但悲观的前景反映了对公司业绩的担忧"
datetime: "2026-03-08T10:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278261754.md)
  - [en](https://longbridge.com/en/news/278261754.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278261754.md)
---

# 美国银行证券在 TG 治疗（TGTX）发布财报后持看空态度

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now. Alec Stranahan of Bank of America reaffirmed a Sell rating on TG Therapeutics, Inc. (NASDAQ:TGTX) with a price target of $15, based on the report released on February 27. The firm’s price target is the lowest among Wall \[…\]

### 相关股票

- [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [TGTX.US](https://longbridge.com/zh-CN/quote/TGTX.US.md)
- [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md)

## 相关资讯与研究

- [减肥药公司 Kailera TherapeuticsIPO 定价 14-16 美元/股 拟周五登陆纳斯达克](https://longbridge.com/zh-CN/news/282645838.md)
- [新一代 COPD 大药来了？](https://longbridge.com/zh-CN/news/282618672.md)
- [“Go Global” 再结硕果！远大医药钇 [90Y] 微球注射液美国临床达终点数据全球领先，驱动全球自主销售放量加速](https://longbridge.com/zh-CN/news/282551870.md)
- [诺和诺德携手 OpenAI 加速药物研发 旨在提升效率](https://longbridge.com/zh-CN/news/282699021.md)
- [凝血障碍生物技术公司 Hemab Therapeutics 申请在美上市 拟筹资至多 1 亿美元](https://longbridge.com/zh-CN/news/282497450.md)